PTC Therapeutics Inc. (PTCT) exhibits 45.0% gross margins and 85.0% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 6.5x enterprise multiple and 4.8% implied options volatility.
Sustained 45.0% gross profitability converts into 50.1% operating margin and 85.0% ROIC, outpacing sector cost of capital.
ROIC: 85.0% // GM: 45.0%YoY revenue trajectory of +114.5% paired with 13.05% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +114.5% // FCF YLD: 13.05%Altman Z-Score of 1.73 and Piotroski F-Score of 9/9 indicate low near-term refinancing stress.
ALTMAN Z: 1.73 // F-SCORE: 9/9Trading at 7.9x trailing P/E (6.6x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 7.9x // EV/EBITDA: 6.5xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $60.88 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 39.5% net margins.
NET MARGIN: 39.5% // D/E: 0.85x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for PTCT & activate live FRED threshold breach alerts.